Pharma & Healthcare
Global Filgrastim and Biosimilars Market Research Report 2026
- Feb 03, 26
- ID: 702530
- Pages: 136
- Figures: 137
- Views: 10
This report delivers a comprehensive overview of the global Filgrastim and Biosimilars market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Filgrastim and Biosimilars. The Filgrastim and Biosimilars market size, estimates, and forecasts are provided in terms of sales volume (K Units) and revenue (US$ millions), with 2025 as the base year and historical and forecast data for 2021–2032.
The report segments the global Filgrastim and Biosimilars market comprehensively. Regional market sizes by Type, by Application, , and by company are also provided. For deeper insight, the report profiles the competitive landscape, key competitors, and their respective market rankings, and discusses technological trends and new product developments.
This report will assist Filgrastim and Biosimilars manufacturers, new entrants, and companies across the industry value chain with information on revenues, sales volume, and average prices for the overall market and its sub-segments, by company, by Type, by Application, and by region.
Market Segmentation
By Company
Amgen
Pfizer
Tanvex BioPharma
Kashiv BioSciences
Sandoz
Teva
Qilu Pharmaceutical
Harbin Pharmaceutical Group
Chengdu Institute of Biological Products
CSPC Baike Biopharma
Shanghai Sunway Biotech
Changchun GeneScience Pharmaceutical
Amoytop Biotech
North China Pharmaceutical
Kexing Biopharm
SL Pharm
Hangzhou Jiuyuan Gene Engineering
Jiangsu Wuzhong Pharmaceutical
Segment by Type
Single-use Vials
Prefilled Syringes
by Application
Hospital and Clinic
Pharmacy
Other
Consumption by Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
Europe
Germany
France
U.K.
Italy
Russia
Latin America
Mexico
Brazil
Argentina
Colombia
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Defines the scope of the report and presents an executive summary of market segments (by Type, by Application, , etc.), including the size of each segment and its future growth potential. It offers a high-level view of the current market and its likely evolution in the short, medium, and long term.
Chapter 2: Provides a detailed analysis of the competitive landscape for Filgrastim and Biosimilars manufacturers, covering pricing, sales and revenue shares, latest development plans, and mergers and acquisitions.
Chapter 3: Examines Filgrastim and Biosimilars sales and revenue at the regional and country levels. It quantifies market size and growth potential for each region and its key countries, and outlines market development, outlook, addressable space, and national market size.
Chapter 4: Analyzes segments by Type, detailing the size and growth potential of each segment to help readers identify “blue ocean” opportunities.
Chapter 5: Analyzes market segments by Application, covering the size and growth potential of each segment to help readers identify “blue ocean” opportunities in downstream markets.
Chapter 6: Profiles key players, presenting core information on leading companies, including product sales, revenue, pricing, gross margin, product portfolio/introductions, and recent developments.
Chapter 7: Reviews the industry value chain, including upstream and downstream segments.
Chapter 8: Discusses market dynamics and recent developments, including drivers, restraints, challenges and risks for manufacturers, U.S. Tariffs and relevant policy analysis.
Chapter 9: Summarizes the key findings and conclusions of the report.
The report segments the global Filgrastim and Biosimilars market comprehensively. Regional market sizes by Type, by Application, , and by company are also provided. For deeper insight, the report profiles the competitive landscape, key competitors, and their respective market rankings, and discusses technological trends and new product developments.
This report will assist Filgrastim and Biosimilars manufacturers, new entrants, and companies across the industry value chain with information on revenues, sales volume, and average prices for the overall market and its sub-segments, by company, by Type, by Application, and by region.
Market Segmentation
By Company
Amgen
Pfizer
Tanvex BioPharma
Kashiv BioSciences
Sandoz
Teva
Qilu Pharmaceutical
Harbin Pharmaceutical Group
Chengdu Institute of Biological Products
CSPC Baike Biopharma
Shanghai Sunway Biotech
Changchun GeneScience Pharmaceutical
Amoytop Biotech
North China Pharmaceutical
Kexing Biopharm
SL Pharm
Hangzhou Jiuyuan Gene Engineering
Jiangsu Wuzhong Pharmaceutical
Segment by Type
Single-use Vials
Prefilled Syringes
by Application
Hospital and Clinic
Pharmacy
Other
Consumption by Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
Europe
Germany
France
U.K.
Italy
Russia
Latin America
Mexico
Brazil
Argentina
Colombia
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Defines the scope of the report and presents an executive summary of market segments (by Type, by Application, , etc.), including the size of each segment and its future growth potential. It offers a high-level view of the current market and its likely evolution in the short, medium, and long term.
Chapter 2: Provides a detailed analysis of the competitive landscape for Filgrastim and Biosimilars manufacturers, covering pricing, sales and revenue shares, latest development plans, and mergers and acquisitions.
Chapter 3: Examines Filgrastim and Biosimilars sales and revenue at the regional and country levels. It quantifies market size and growth potential for each region and its key countries, and outlines market development, outlook, addressable space, and national market size.
Chapter 4: Analyzes segments by Type, detailing the size and growth potential of each segment to help readers identify “blue ocean” opportunities.
Chapter 5: Analyzes market segments by Application, covering the size and growth potential of each segment to help readers identify “blue ocean” opportunities in downstream markets.
Chapter 6: Profiles key players, presenting core information on leading companies, including product sales, revenue, pricing, gross margin, product portfolio/introductions, and recent developments.
Chapter 7: Reviews the industry value chain, including upstream and downstream segments.
Chapter 8: Discusses market dynamics and recent developments, including drivers, restraints, challenges and risks for manufacturers, U.S. Tariffs and relevant policy analysis.
Chapter 9: Summarizes the key findings and conclusions of the report.
1 Filgrastim and Biosimilars Market Overview
1.1 Product Definition
1.2 Filgrastim and Biosimilars by Type
1.2.1 Global Filgrastim and Biosimilars Market Value by Type: 2025 vs 2032
1.2.2 Single-use Vials
1.2.3 Prefilled Syringes
1.3 Filgrastim and Biosimilars by Application
1.3.1 Global Filgrastim and Biosimilars Market Value by Application: 2025 vs 2032
1.3.2 Hospital and Clinic
1.3.3 Pharmacy
1.3.4 Other
1.4 Global Filgrastim and Biosimilars Market Size Estimates and Forecasts
1.4.1 Global Filgrastim and Biosimilars Revenue 2021–2032
1.4.2 Global Filgrastim and Biosimilars Sales 2021–2032
1.4.3 Global Filgrastim and Biosimilars Market Average Price (2021–2032)
1.5 Assumptions and Limitations
2 Filgrastim and Biosimilars Market Competition by Manufacturers
2.1 Global Filgrastim and Biosimilars Sales Market Share by Manufacturers (2021–2026)
2.2 Global Filgrastim and Biosimilars Revenue Market Share by Manufacturers (2021–2026)
2.3 Global Filgrastim and Biosimilars Average Price by Manufacturers (2021–2026)
2.4 Global Key Players of Filgrastim and Biosimilars, Industry Ranking, 2023 vs 2024 vs 2025
2.5 Global Key Manufacturers of Filgrastim and Biosimilars, Manufacturing Sites and Headquarters
2.6 Global Key Manufacturers of Filgrastim and Biosimilars, Product Types and Applications
2.7 Global Key Manufacturers of Filgrastim and Biosimilars, Date of Entry into the Industry
2.8 Global Filgrastim and Biosimilars Market Competitive Situation and Trends
2.8.1 Global Filgrastim and Biosimilars Market Concentration Rate
2.8.2 The Top 5 and Top 10 Global Filgrastim and Biosimilars Players Market Share by Revenue
2.8.3 Global Filgrastim and Biosimilars Market Share by Company Tier (Tier 1, Tier 2, Tier 3)
2.9 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Global Filgrastim and Biosimilars Market Scenario by Region
3.1 Global Filgrastim and Biosimilars Market Size by Region: 2021 vs 2025 vs 2032
3.2 Global Filgrastim and Biosimilars Sales by Region: 2021–2032
3.2.1 Global Filgrastim and Biosimilars Sales by Region: 2021–2026
3.2.2 Global Filgrastim and Biosimilars Sales by Region: 2027–2032
3.3 Global Filgrastim and Biosimilars Revenue by Region: 2021–2032
3.3.1 Global Filgrastim and Biosimilars Revenue by Region: 2021–2026
3.3.2 Global Filgrastim and Biosimilars Revenue by Region: 2027–2032
3.4 North America Filgrastim and Biosimilars Market Facts & Figures by Country
3.4.1 North America Filgrastim and Biosimilars Market Size by Country: 2021 vs 2025 vs 2032
3.4.2 North America Filgrastim and Biosimilars Sales by Country (2021–2032)
3.4.3 North America Filgrastim and Biosimilars Revenue by Country (2021–2032)
3.4.4 United States
3.4.5 Canada
3.5 Europe Filgrastim and Biosimilars Market Facts & Figures by Country
3.5.1 Europe Filgrastim and Biosimilars Market Size by Country: 2021 vs 2025 vs 2032
3.5.2 Europe Filgrastim and Biosimilars Sales by Country (2021–2032)
3.5.3 Europe Filgrastim and Biosimilars Revenue by Country (2021–2032)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Filgrastim and Biosimilars Market Facts & Figures by Region
3.6.1 Asia Pacific Filgrastim and Biosimilars Market Size by Region: 2021 vs 2025 vs 2032
3.6.2 Asia Pacific Filgrastim and Biosimilars Sales by Region (2021–2032)
3.6.3 Asia Pacific Filgrastim and Biosimilars Revenue by Region (2021–2032)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Southeast Asia
3.7 Latin America Filgrastim and Biosimilars Market Facts & Figures by Country
3.7.1 Latin America Filgrastim and Biosimilars Market Size by Country: 2021 vs 2025 vs 2032
3.7.2 Latin America Filgrastim and Biosimilars Sales by Country (2021–2032)
3.7.3 Latin America Filgrastim and Biosimilars Revenue by Country (2021–2032)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.7.7 Colombia
3.8 Middle East and Africa Filgrastim and Biosimilars Market Facts & Figures by Country
3.8.1 Middle East and Africa Filgrastim and Biosimilars Market Size by Country: 2021 vs 2025 vs 2032
3.8.2 Middle East and Africa Filgrastim and Biosimilars Sales by Country (2021–2032)
3.8.3 Middle East and Africa Filgrastim and Biosimilars Revenue by Country (2021–2032)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Filgrastim and Biosimilars Sales by Type (2021–2032)
4.1.1 Global Filgrastim and Biosimilars Sales by Type (2021–2026)
4.1.2 Global Filgrastim and Biosimilars Sales by Type (2027–2032)
4.1.3 Global Filgrastim and Biosimilars Sales Market Share by Type (2021–2032)
4.2 Global Filgrastim and Biosimilars Revenue by Type (2021–2032)
4.2.1 Global Filgrastim and Biosimilars Revenue by Type (2021–2026)
4.2.2 Global Filgrastim and Biosimilars Revenue by Type (2027–2032)
4.2.3 Global Filgrastim and Biosimilars Revenue Market Share by Type (2021–2032)
4.3 Global Filgrastim and Biosimilars Price by Type (2021–2032)
5 Segment by Application
5.1 Global Filgrastim and Biosimilars Sales by Application (2021–2032)
5.1.1 Global Filgrastim and Biosimilars Sales by Application (2021–2026)
5.1.2 Global Filgrastim and Biosimilars Sales by Application (2027–2032)
5.1.3 Global Filgrastim and Biosimilars Sales Market Share by Application (2021–2032)
5.2 Global Filgrastim and Biosimilars Revenue by Application (2021–2032)
5.2.1 Global Filgrastim and Biosimilars Revenue by Application (2021–2026)
5.2.2 Global Filgrastim and Biosimilars Revenue by Application (2027–2032)
5.2.3 Global Filgrastim and Biosimilars Revenue Market Share by Application (2021–2032)
5.3 Global Filgrastim and Biosimilars Price by Application (2021–2032)
6 Key Companies Profiled
6.1 Amgen
6.1.1 Amgen Company Information
6.1.2 Amgen Description and Business Overview
6.1.3 Amgen Filgrastim and Biosimilars Sales, Revenue, and Gross Margin (2021–2026)
6.1.4 Amgen Filgrastim and Biosimilars Product Portfolio
6.1.5 Amgen Recent Developments/Updates
6.2 Pfizer
6.2.1 Pfizer Company Information
6.2.2 Pfizer Description and Business Overview
6.2.3 Pfizer Filgrastim and Biosimilars Sales, Revenue, and Gross Margin (2021–2026)
6.2.4 Pfizer Filgrastim and Biosimilars Product Portfolio
6.2.5 Pfizer Recent Developments/Updates
6.3 Tanvex BioPharma
6.3.1 Tanvex BioPharma Company Information
6.3.2 Tanvex BioPharma Description and Business Overview
6.3.3 Tanvex BioPharma Filgrastim and Biosimilars Sales, Revenue, and Gross Margin (2021–2026)
6.3.4 Tanvex BioPharma Filgrastim and Biosimilars Product Portfolio
6.3.5 Tanvex BioPharma Recent Developments/Updates
6.4 Kashiv BioSciences
6.4.1 Kashiv BioSciences Company Information
6.4.2 Kashiv BioSciences Description and Business Overview
6.4.3 Kashiv BioSciences Filgrastim and Biosimilars Sales, Revenue, and Gross Margin (2021–2026)
6.4.4 Kashiv BioSciences Filgrastim and Biosimilars Product Portfolio
6.4.5 Kashiv BioSciences Recent Developments/Updates
6.5 Sandoz
6.5.1 Sandoz Company Information
6.5.2 Sandoz Description and Business Overview
6.5.3 Sandoz Filgrastim and Biosimilars Sales, Revenue, and Gross Margin (2021–2026)
6.5.4 Sandoz Filgrastim and Biosimilars Product Portfolio
6.5.5 Sandoz Recent Developments/Updates
6.6 Teva
6.6.1 Teva Company Information
6.6.2 Teva Description and Business Overview
6.6.3 Teva Filgrastim and Biosimilars Sales, Revenue, and Gross Margin (2021–2026)
6.6.4 Teva Filgrastim and Biosimilars Product Portfolio
6.6.5 Teva Recent Developments/Updates
6.7 Qilu Pharmaceutical
6.7.1 Qilu Pharmaceutical Company Information
6.7.2 Qilu Pharmaceutical Description and Business Overview
6.7.3 Qilu Pharmaceutical Filgrastim and Biosimilars Sales, Revenue, and Gross Margin (2021–2026)
6.7.4 Qilu Pharmaceutical Filgrastim and Biosimilars Product Portfolio
6.7.5 Qilu Pharmaceutical Recent Developments/Updates
6.8 Harbin Pharmaceutical Group
6.8.1 Harbin Pharmaceutical Group Company Information
6.8.2 Harbin Pharmaceutical Group Description and Business Overview
6.8.3 Harbin Pharmaceutical Group Filgrastim and Biosimilars Sales, Revenue, and Gross Margin (2021–2026)
6.8.4 Harbin Pharmaceutical Group Filgrastim and Biosimilars Product Portfolio
6.8.5 Harbin Pharmaceutical Group Recent Developments/Updates
6.9 Chengdu Institute of Biological Products
6.9.1 Chengdu Institute of Biological Products Company Information
6.9.2 Chengdu Institute of Biological Products Description and Business Overview
6.9.3 Chengdu Institute of Biological Products Filgrastim and Biosimilars Sales, Revenue, and Gross Margin (2021–2026)
6.9.4 Chengdu Institute of Biological Products Filgrastim and Biosimilars Product Portfolio
6.9.5 Chengdu Institute of Biological Products Recent Developments/Updates
6.10 CSPC Baike Biopharma
6.10.1 CSPC Baike Biopharma Company Information
6.10.2 CSPC Baike Biopharma Description and Business Overview
6.10.3 CSPC Baike Biopharma Filgrastim and Biosimilars Sales, Revenue, and Gross Margin (2021–2026)
6.10.4 CSPC Baike Biopharma Filgrastim and Biosimilars Product Portfolio
6.10.5 CSPC Baike Biopharma Recent Developments/Updates
6.11 Shanghai Sunway Biotech
6.11.1 Shanghai Sunway Biotech Company Information
6.11.2 Shanghai Sunway Biotech Description and Business Overview
6.11.3 Shanghai Sunway Biotech Filgrastim and Biosimilars Sales, Revenue, and Gross Margin (2021–2026)
6.11.4 Shanghai Sunway Biotech Filgrastim and Biosimilars Product Portfolio
6.11.5 Shanghai Sunway Biotech Recent Developments/Updates
6.12 Changchun GeneScience Pharmaceutical
6.12.1 Changchun GeneScience Pharmaceutical Company Information
6.12.2 Changchun GeneScience Pharmaceutical Description and Business Overview
6.12.3 Changchun GeneScience Pharmaceutical Filgrastim and Biosimilars Sales, Revenue, and Gross Margin (2021–2026)
6.12.4 Changchun GeneScience Pharmaceutical Filgrastim and Biosimilars Product Portfolio
6.12.5 Changchun GeneScience Pharmaceutical Recent Developments/Updates
6.13 Amoytop Biotech
6.13.1 Amoytop Biotech Company Information
6.13.2 Amoytop Biotech Description and Business Overview
6.13.3 Amoytop Biotech Filgrastim and Biosimilars Sales, Revenue, and Gross Margin (2021–2026)
6.13.4 Amoytop Biotech Filgrastim and Biosimilars Product Portfolio
6.13.5 Amoytop Biotech Recent Developments/Updates
6.14 North China Pharmaceutical
6.14.1 North China Pharmaceutical Company Information
6.14.2 North China Pharmaceutical Description and Business Overview
6.14.3 North China Pharmaceutical Filgrastim and Biosimilars Sales, Revenue, and Gross Margin (2021–2026)
6.14.4 North China Pharmaceutical Filgrastim and Biosimilars Product Portfolio
6.14.5 North China Pharmaceutical Recent Developments/Updates
6.15 Kexing Biopharm
6.15.1 Kexing Biopharm Company Information
6.15.2 Kexing Biopharm Description and Business Overview
6.15.3 Kexing Biopharm Filgrastim and Biosimilars Sales, Revenue, and Gross Margin (2021–2026)
6.15.4 Kexing Biopharm Filgrastim and Biosimilars Product Portfolio
6.15.5 Kexing Biopharm Recent Developments/Updates
6.16 SL Pharm
6.16.1 SL Pharm Company Information
6.16.2 SL Pharm Description and Business Overview
6.16.3 SL Pharm Filgrastim and Biosimilars Sales, Revenue, and Gross Margin (2021–2026)
6.16.4 SL Pharm Filgrastim and Biosimilars Product Portfolio
6.16.5 SL Pharm Recent Developments/Updates
6.17 Hangzhou Jiuyuan Gene Engineering
6.17.1 Hangzhou Jiuyuan Gene Engineering Company Information
6.17.2 Hangzhou Jiuyuan Gene Engineering Description and Business Overview
6.17.3 Hangzhou Jiuyuan Gene Engineering Filgrastim and Biosimilars Sales, Revenue, and Gross Margin (2021–2026)
6.17.4 Hangzhou Jiuyuan Gene Engineering Filgrastim and Biosimilars Product Portfolio
6.17.5 Hangzhou Jiuyuan Gene Engineering Recent Developments/Updates
6.18 Jiangsu Wuzhong Pharmaceutical
6.18.1 Jiangsu Wuzhong Pharmaceutical Company Information
6.18.2 Jiangsu Wuzhong Pharmaceutical Description and Business Overview
6.18.3 Jiangsu Wuzhong Pharmaceutical Filgrastim and Biosimilars Sales, Revenue, and Gross Margin (2021–2026)
6.18.4 Jiangsu Wuzhong Pharmaceutical Filgrastim and Biosimilars Product Portfolio
6.18.5 Jiangsu Wuzhong Pharmaceutical Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Filgrastim and Biosimilars Industry Chain Analysis
7.2 Filgrastim and Biosimilars Raw Material Supply Analysis
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Filgrastim and Biosimilars Production Mode & Process Analysis
7.4 Filgrastim and Biosimilars Sales and Marketing
7.4.1 Filgrastim and Biosimilars Sales Channels
7.4.2 Filgrastim and Biosimilars Distributors
7.5 Filgrastim and Biosimilars Customer Analysis
8 Filgrastim and Biosimilars Market Dynamics
8.1 Filgrastim and Biosimilars Industry Trends
8.2 Filgrastim and Biosimilars Market Drivers
8.3 Filgrastim and Biosimilars Market Challenges
8.4 Filgrastim and Biosimilars Market Restraints
8.5 Impact of U.S. Tariffs
9 Research Findings and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
1.1 Product Definition
1.2 Filgrastim and Biosimilars by Type
1.2.1 Global Filgrastim and Biosimilars Market Value by Type: 2025 vs 2032
1.2.2 Single-use Vials
1.2.3 Prefilled Syringes
1.3 Filgrastim and Biosimilars by Application
1.3.1 Global Filgrastim and Biosimilars Market Value by Application: 2025 vs 2032
1.3.2 Hospital and Clinic
1.3.3 Pharmacy
1.3.4 Other
1.4 Global Filgrastim and Biosimilars Market Size Estimates and Forecasts
1.4.1 Global Filgrastim and Biosimilars Revenue 2021–2032
1.4.2 Global Filgrastim and Biosimilars Sales 2021–2032
1.4.3 Global Filgrastim and Biosimilars Market Average Price (2021–2032)
1.5 Assumptions and Limitations
2 Filgrastim and Biosimilars Market Competition by Manufacturers
2.1 Global Filgrastim and Biosimilars Sales Market Share by Manufacturers (2021–2026)
2.2 Global Filgrastim and Biosimilars Revenue Market Share by Manufacturers (2021–2026)
2.3 Global Filgrastim and Biosimilars Average Price by Manufacturers (2021–2026)
2.4 Global Key Players of Filgrastim and Biosimilars, Industry Ranking, 2023 vs 2024 vs 2025
2.5 Global Key Manufacturers of Filgrastim and Biosimilars, Manufacturing Sites and Headquarters
2.6 Global Key Manufacturers of Filgrastim and Biosimilars, Product Types and Applications
2.7 Global Key Manufacturers of Filgrastim and Biosimilars, Date of Entry into the Industry
2.8 Global Filgrastim and Biosimilars Market Competitive Situation and Trends
2.8.1 Global Filgrastim and Biosimilars Market Concentration Rate
2.8.2 The Top 5 and Top 10 Global Filgrastim and Biosimilars Players Market Share by Revenue
2.8.3 Global Filgrastim and Biosimilars Market Share by Company Tier (Tier 1, Tier 2, Tier 3)
2.9 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Global Filgrastim and Biosimilars Market Scenario by Region
3.1 Global Filgrastim and Biosimilars Market Size by Region: 2021 vs 2025 vs 2032
3.2 Global Filgrastim and Biosimilars Sales by Region: 2021–2032
3.2.1 Global Filgrastim and Biosimilars Sales by Region: 2021–2026
3.2.2 Global Filgrastim and Biosimilars Sales by Region: 2027–2032
3.3 Global Filgrastim and Biosimilars Revenue by Region: 2021–2032
3.3.1 Global Filgrastim and Biosimilars Revenue by Region: 2021–2026
3.3.2 Global Filgrastim and Biosimilars Revenue by Region: 2027–2032
3.4 North America Filgrastim and Biosimilars Market Facts & Figures by Country
3.4.1 North America Filgrastim and Biosimilars Market Size by Country: 2021 vs 2025 vs 2032
3.4.2 North America Filgrastim and Biosimilars Sales by Country (2021–2032)
3.4.3 North America Filgrastim and Biosimilars Revenue by Country (2021–2032)
3.4.4 United States
3.4.5 Canada
3.5 Europe Filgrastim and Biosimilars Market Facts & Figures by Country
3.5.1 Europe Filgrastim and Biosimilars Market Size by Country: 2021 vs 2025 vs 2032
3.5.2 Europe Filgrastim and Biosimilars Sales by Country (2021–2032)
3.5.3 Europe Filgrastim and Biosimilars Revenue by Country (2021–2032)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Filgrastim and Biosimilars Market Facts & Figures by Region
3.6.1 Asia Pacific Filgrastim and Biosimilars Market Size by Region: 2021 vs 2025 vs 2032
3.6.2 Asia Pacific Filgrastim and Biosimilars Sales by Region (2021–2032)
3.6.3 Asia Pacific Filgrastim and Biosimilars Revenue by Region (2021–2032)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Southeast Asia
3.7 Latin America Filgrastim and Biosimilars Market Facts & Figures by Country
3.7.1 Latin America Filgrastim and Biosimilars Market Size by Country: 2021 vs 2025 vs 2032
3.7.2 Latin America Filgrastim and Biosimilars Sales by Country (2021–2032)
3.7.3 Latin America Filgrastim and Biosimilars Revenue by Country (2021–2032)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.7.7 Colombia
3.8 Middle East and Africa Filgrastim and Biosimilars Market Facts & Figures by Country
3.8.1 Middle East and Africa Filgrastim and Biosimilars Market Size by Country: 2021 vs 2025 vs 2032
3.8.2 Middle East and Africa Filgrastim and Biosimilars Sales by Country (2021–2032)
3.8.3 Middle East and Africa Filgrastim and Biosimilars Revenue by Country (2021–2032)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Filgrastim and Biosimilars Sales by Type (2021–2032)
4.1.1 Global Filgrastim and Biosimilars Sales by Type (2021–2026)
4.1.2 Global Filgrastim and Biosimilars Sales by Type (2027–2032)
4.1.3 Global Filgrastim and Biosimilars Sales Market Share by Type (2021–2032)
4.2 Global Filgrastim and Biosimilars Revenue by Type (2021–2032)
4.2.1 Global Filgrastim and Biosimilars Revenue by Type (2021–2026)
4.2.2 Global Filgrastim and Biosimilars Revenue by Type (2027–2032)
4.2.3 Global Filgrastim and Biosimilars Revenue Market Share by Type (2021–2032)
4.3 Global Filgrastim and Biosimilars Price by Type (2021–2032)
5 Segment by Application
5.1 Global Filgrastim and Biosimilars Sales by Application (2021–2032)
5.1.1 Global Filgrastim and Biosimilars Sales by Application (2021–2026)
5.1.2 Global Filgrastim and Biosimilars Sales by Application (2027–2032)
5.1.3 Global Filgrastim and Biosimilars Sales Market Share by Application (2021–2032)
5.2 Global Filgrastim and Biosimilars Revenue by Application (2021–2032)
5.2.1 Global Filgrastim and Biosimilars Revenue by Application (2021–2026)
5.2.2 Global Filgrastim and Biosimilars Revenue by Application (2027–2032)
5.2.3 Global Filgrastim and Biosimilars Revenue Market Share by Application (2021–2032)
5.3 Global Filgrastim and Biosimilars Price by Application (2021–2032)
6 Key Companies Profiled
6.1 Amgen
6.1.1 Amgen Company Information
6.1.2 Amgen Description and Business Overview
6.1.3 Amgen Filgrastim and Biosimilars Sales, Revenue, and Gross Margin (2021–2026)
6.1.4 Amgen Filgrastim and Biosimilars Product Portfolio
6.1.5 Amgen Recent Developments/Updates
6.2 Pfizer
6.2.1 Pfizer Company Information
6.2.2 Pfizer Description and Business Overview
6.2.3 Pfizer Filgrastim and Biosimilars Sales, Revenue, and Gross Margin (2021–2026)
6.2.4 Pfizer Filgrastim and Biosimilars Product Portfolio
6.2.5 Pfizer Recent Developments/Updates
6.3 Tanvex BioPharma
6.3.1 Tanvex BioPharma Company Information
6.3.2 Tanvex BioPharma Description and Business Overview
6.3.3 Tanvex BioPharma Filgrastim and Biosimilars Sales, Revenue, and Gross Margin (2021–2026)
6.3.4 Tanvex BioPharma Filgrastim and Biosimilars Product Portfolio
6.3.5 Tanvex BioPharma Recent Developments/Updates
6.4 Kashiv BioSciences
6.4.1 Kashiv BioSciences Company Information
6.4.2 Kashiv BioSciences Description and Business Overview
6.4.3 Kashiv BioSciences Filgrastim and Biosimilars Sales, Revenue, and Gross Margin (2021–2026)
6.4.4 Kashiv BioSciences Filgrastim and Biosimilars Product Portfolio
6.4.5 Kashiv BioSciences Recent Developments/Updates
6.5 Sandoz
6.5.1 Sandoz Company Information
6.5.2 Sandoz Description and Business Overview
6.5.3 Sandoz Filgrastim and Biosimilars Sales, Revenue, and Gross Margin (2021–2026)
6.5.4 Sandoz Filgrastim and Biosimilars Product Portfolio
6.5.5 Sandoz Recent Developments/Updates
6.6 Teva
6.6.1 Teva Company Information
6.6.2 Teva Description and Business Overview
6.6.3 Teva Filgrastim and Biosimilars Sales, Revenue, and Gross Margin (2021–2026)
6.6.4 Teva Filgrastim and Biosimilars Product Portfolio
6.6.5 Teva Recent Developments/Updates
6.7 Qilu Pharmaceutical
6.7.1 Qilu Pharmaceutical Company Information
6.7.2 Qilu Pharmaceutical Description and Business Overview
6.7.3 Qilu Pharmaceutical Filgrastim and Biosimilars Sales, Revenue, and Gross Margin (2021–2026)
6.7.4 Qilu Pharmaceutical Filgrastim and Biosimilars Product Portfolio
6.7.5 Qilu Pharmaceutical Recent Developments/Updates
6.8 Harbin Pharmaceutical Group
6.8.1 Harbin Pharmaceutical Group Company Information
6.8.2 Harbin Pharmaceutical Group Description and Business Overview
6.8.3 Harbin Pharmaceutical Group Filgrastim and Biosimilars Sales, Revenue, and Gross Margin (2021–2026)
6.8.4 Harbin Pharmaceutical Group Filgrastim and Biosimilars Product Portfolio
6.8.5 Harbin Pharmaceutical Group Recent Developments/Updates
6.9 Chengdu Institute of Biological Products
6.9.1 Chengdu Institute of Biological Products Company Information
6.9.2 Chengdu Institute of Biological Products Description and Business Overview
6.9.3 Chengdu Institute of Biological Products Filgrastim and Biosimilars Sales, Revenue, and Gross Margin (2021–2026)
6.9.4 Chengdu Institute of Biological Products Filgrastim and Biosimilars Product Portfolio
6.9.5 Chengdu Institute of Biological Products Recent Developments/Updates
6.10 CSPC Baike Biopharma
6.10.1 CSPC Baike Biopharma Company Information
6.10.2 CSPC Baike Biopharma Description and Business Overview
6.10.3 CSPC Baike Biopharma Filgrastim and Biosimilars Sales, Revenue, and Gross Margin (2021–2026)
6.10.4 CSPC Baike Biopharma Filgrastim and Biosimilars Product Portfolio
6.10.5 CSPC Baike Biopharma Recent Developments/Updates
6.11 Shanghai Sunway Biotech
6.11.1 Shanghai Sunway Biotech Company Information
6.11.2 Shanghai Sunway Biotech Description and Business Overview
6.11.3 Shanghai Sunway Biotech Filgrastim and Biosimilars Sales, Revenue, and Gross Margin (2021–2026)
6.11.4 Shanghai Sunway Biotech Filgrastim and Biosimilars Product Portfolio
6.11.5 Shanghai Sunway Biotech Recent Developments/Updates
6.12 Changchun GeneScience Pharmaceutical
6.12.1 Changchun GeneScience Pharmaceutical Company Information
6.12.2 Changchun GeneScience Pharmaceutical Description and Business Overview
6.12.3 Changchun GeneScience Pharmaceutical Filgrastim and Biosimilars Sales, Revenue, and Gross Margin (2021–2026)
6.12.4 Changchun GeneScience Pharmaceutical Filgrastim and Biosimilars Product Portfolio
6.12.5 Changchun GeneScience Pharmaceutical Recent Developments/Updates
6.13 Amoytop Biotech
6.13.1 Amoytop Biotech Company Information
6.13.2 Amoytop Biotech Description and Business Overview
6.13.3 Amoytop Biotech Filgrastim and Biosimilars Sales, Revenue, and Gross Margin (2021–2026)
6.13.4 Amoytop Biotech Filgrastim and Biosimilars Product Portfolio
6.13.5 Amoytop Biotech Recent Developments/Updates
6.14 North China Pharmaceutical
6.14.1 North China Pharmaceutical Company Information
6.14.2 North China Pharmaceutical Description and Business Overview
6.14.3 North China Pharmaceutical Filgrastim and Biosimilars Sales, Revenue, and Gross Margin (2021–2026)
6.14.4 North China Pharmaceutical Filgrastim and Biosimilars Product Portfolio
6.14.5 North China Pharmaceutical Recent Developments/Updates
6.15 Kexing Biopharm
6.15.1 Kexing Biopharm Company Information
6.15.2 Kexing Biopharm Description and Business Overview
6.15.3 Kexing Biopharm Filgrastim and Biosimilars Sales, Revenue, and Gross Margin (2021–2026)
6.15.4 Kexing Biopharm Filgrastim and Biosimilars Product Portfolio
6.15.5 Kexing Biopharm Recent Developments/Updates
6.16 SL Pharm
6.16.1 SL Pharm Company Information
6.16.2 SL Pharm Description and Business Overview
6.16.3 SL Pharm Filgrastim and Biosimilars Sales, Revenue, and Gross Margin (2021–2026)
6.16.4 SL Pharm Filgrastim and Biosimilars Product Portfolio
6.16.5 SL Pharm Recent Developments/Updates
6.17 Hangzhou Jiuyuan Gene Engineering
6.17.1 Hangzhou Jiuyuan Gene Engineering Company Information
6.17.2 Hangzhou Jiuyuan Gene Engineering Description and Business Overview
6.17.3 Hangzhou Jiuyuan Gene Engineering Filgrastim and Biosimilars Sales, Revenue, and Gross Margin (2021–2026)
6.17.4 Hangzhou Jiuyuan Gene Engineering Filgrastim and Biosimilars Product Portfolio
6.17.5 Hangzhou Jiuyuan Gene Engineering Recent Developments/Updates
6.18 Jiangsu Wuzhong Pharmaceutical
6.18.1 Jiangsu Wuzhong Pharmaceutical Company Information
6.18.2 Jiangsu Wuzhong Pharmaceutical Description and Business Overview
6.18.3 Jiangsu Wuzhong Pharmaceutical Filgrastim and Biosimilars Sales, Revenue, and Gross Margin (2021–2026)
6.18.4 Jiangsu Wuzhong Pharmaceutical Filgrastim and Biosimilars Product Portfolio
6.18.5 Jiangsu Wuzhong Pharmaceutical Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Filgrastim and Biosimilars Industry Chain Analysis
7.2 Filgrastim and Biosimilars Raw Material Supply Analysis
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Filgrastim and Biosimilars Production Mode & Process Analysis
7.4 Filgrastim and Biosimilars Sales and Marketing
7.4.1 Filgrastim and Biosimilars Sales Channels
7.4.2 Filgrastim and Biosimilars Distributors
7.5 Filgrastim and Biosimilars Customer Analysis
8 Filgrastim and Biosimilars Market Dynamics
8.1 Filgrastim and Biosimilars Industry Trends
8.2 Filgrastim and Biosimilars Market Drivers
8.3 Filgrastim and Biosimilars Market Challenges
8.4 Filgrastim and Biosimilars Market Restraints
8.5 Impact of U.S. Tariffs
9 Research Findings and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
List of Tables
Table 1. Global Filgrastim and Biosimilars Market Value by Type (US$ Million), 2025 vs 2032
Table 2. Global Filgrastim and Biosimilars Market Value by Application (US$ Million), 2025 vs 2032
Table 3. Global Filgrastim and Biosimilars Market Competitive Situation by Manufacturers in 2025
Table 4. Global Filgrastim and Biosimilars Sales (K Units) of Key Manufacturers (2021–2026)
Table 5. Global Filgrastim and Biosimilars Sales Market Share by Manufacturers (2021–2026)
Table 6. Global Filgrastim and Biosimilars Revenue (US$ Million) by Manufacturers (2021–2026)
Table 7. Global Filgrastim and Biosimilars Revenue Share by Manufacturers (2021–2026)
Table 8. Global Market Filgrastim and Biosimilars Average Price (US$/Unit) of Key Manufacturers (2021–2026)
Table 9. Global Key Players of Filgrastim and Biosimilars, Industry Ranking, 2023 vs 2024 vs 2025
Table 10. Global Key Manufacturers of Filgrastim and Biosimilars, Manufacturing Sites and Headquarters
Table 11. Global Key Manufacturers of Filgrastim and Biosimilars, Product Types and Applications
Table 12. Global Key Manufacturers of Filgrastim and Biosimilars, Date of Entry into the Industry
Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Global Filgrastim and Biosimilars Companies by Tier (Tier 1, Tier 2, Tier 3), based on Filgrastim and Biosimilars Revenue, 2025
Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 16. Global Filgrastim and Biosimilars Market Size by Region (US$ Million): 2021 vs 2025 vs 2032
Table 17. Global Filgrastim and Biosimilars Sales by Region (K Units), 2021–2026
Table 18. Global Filgrastim and Biosimilars Sales Market Share by Region (2021–2026)
Table 19. Global Filgrastim and Biosimilars Sales by Region (K Units), 2027–2032
Table 20. Global Filgrastim and Biosimilars Sales Market Share by Region (2027–2032)
Table 21. Global Filgrastim and Biosimilars Revenue by Region (US$ Million), 2021–2026
Table 22. Global Filgrastim and Biosimilars Revenue Market Share by Region (2021–2026)
Table 23. Global Filgrastim and Biosimilars Revenue by Region (US$ Million), 2027–2032
Table 24. Global Filgrastim and Biosimilars Revenue Market Share by Region (2027–2032)
Table 25. North America Filgrastim and Biosimilars Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 26. North America Filgrastim and Biosimilars Sales by Country (K Units), 2021–2026
Table 27. North America Filgrastim and Biosimilars Sales by Country (K Units), 2027–2032
Table 28. North America Filgrastim and Biosimilars Revenue by Country (US$ Million), 2021–2026
Table 29. North America Filgrastim and Biosimilars Revenue by Country (US$ Million), 2027–2032
Table 30. Europe Filgrastim and Biosimilars Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 31. Europe Filgrastim and Biosimilars Sales by Country (K Units), 2021–2026
Table 32. Europe Filgrastim and Biosimilars Sales by Country (K Units), 2027–2032
Table 33. Europe Filgrastim and Biosimilars Revenue by Country (US$ Million), 2021–2026
Table 34. Europe Filgrastim and Biosimilars Revenue by Country (US$ Million), 2027–2032
Table 35. Asia Pacific Filgrastim and Biosimilars Revenue by Region: 2021 vs 2025 vs 2032 (US$ Million)
Table 36. Asia Pacific Filgrastim and Biosimilars Sales by Region (K Units), 2021–2026
Table 37. Asia Pacific Filgrastim and Biosimilars Sales by Region (K Units), 2027–2032
Table 38. Asia Pacific Filgrastim and Biosimilars Revenue by Region (US$ Million), 2021–2026
Table 39. Asia Pacific Filgrastim and Biosimilars Revenue by Region (US$ Million), 2027–2032
Table 40. Latin America Filgrastim and Biosimilars Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 41. Latin America Filgrastim and Biosimilars Sales by Country (K Units), 2021–2026
Table 42. Latin America Filgrastim and Biosimilars Sales by Country (K Units), 2027–2032
Table 43. Latin America Filgrastim and Biosimilars Revenue by Country (US$ Million), 2021–2026
Table 44. Latin America Filgrastim and Biosimilars Revenue by Country (US$ Million), 2027–2032
Table 45. Middle East and Africa Filgrastim and Biosimilars Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 46. Middle East and Africa Filgrastim and Biosimilars Sales by Country (K Units), 2021–2026
Table 47. Middle East and Africa Filgrastim and Biosimilars Sales by Country (K Units), 2027–2032
Table 48. Middle East and Africa Filgrastim and Biosimilars Revenue by Country (US$ Million), 2021–2026
Table 49. Middle East and Africa Filgrastim and Biosimilars Revenue by Country (US$ Million), 2027–2032
Table 50. Global Filgrastim and Biosimilars Sales (K Units) by Type (2021–2026)
Table 51. Global Filgrastim and Biosimilars Sales (K Units) by Type (2027–2032)
Table 52. Global Filgrastim and Biosimilars Sales Market Share by Type (2021–2026)
Table 53. Global Filgrastim and Biosimilars Sales Market Share by Type (2027–2032)
Table 54. Global Filgrastim and Biosimilars Revenue (US$ Million) by Type (2021–2026)
Table 55. Global Filgrastim and Biosimilars Revenue (US$ Million) by Type (2027–2032)
Table 56. Global Filgrastim and Biosimilars Revenue Market Share by Type (2021–2026)
Table 57. Global Filgrastim and Biosimilars Revenue Market Share by Type (2027–2032)
Table 58. Global Filgrastim and Biosimilars Price (US$/Unit) by Type (2021–2026)
Table 59. Global Filgrastim and Biosimilars Price (US$/Unit) by Type (2027–2032)
Table 60. Global Filgrastim and Biosimilars Sales (K Units) by Application (2021–2026)
Table 61. Global Filgrastim and Biosimilars Sales (K Units) by Application (2027–2032)
Table 62. Global Filgrastim and Biosimilars Sales Market Share by Application (2021–2026)
Table 63. Global Filgrastim and Biosimilars Sales Market Share by Application (2027–2032)
Table 64. Global Filgrastim and Biosimilars Revenue (US$ Million) by Application (2021–2026)
Table 65. Global Filgrastim and Biosimilars Revenue (US$ Million) by Application (2027–2032)
Table 66. Global Filgrastim and Biosimilars Revenue Market Share by Application (2021–2026)
Table 67. Global Filgrastim and Biosimilars Revenue Market Share by Application (2027–2032)
Table 68. Global Filgrastim and Biosimilars Price (US$/Unit) by Application (2021–2026)
Table 69. Global Filgrastim and Biosimilars Price (US$/Unit) by Application (2027–2032)
Table 70. Amgen Company Information
Table 71. Amgen Description and Business Overview
Table 72. Amgen Filgrastim and Biosimilars Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 73. Amgen Filgrastim and Biosimilars Product
Table 74. Amgen Recent Developments/Updates
Table 75. Pfizer Company Information
Table 76. Pfizer Description and Business Overview
Table 77. Pfizer Filgrastim and Biosimilars Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 78. Pfizer Filgrastim and Biosimilars Product
Table 79. Pfizer Recent Developments/Updates
Table 80. Tanvex BioPharma Company Information
Table 81. Tanvex BioPharma Description and Business Overview
Table 82. Tanvex BioPharma Filgrastim and Biosimilars Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 83. Tanvex BioPharma Filgrastim and Biosimilars Product
Table 84. Tanvex BioPharma Recent Developments/Updates
Table 85. Kashiv BioSciences Company Information
Table 86. Kashiv BioSciences Description and Business Overview
Table 87. Kashiv BioSciences Filgrastim and Biosimilars Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 88. Kashiv BioSciences Filgrastim and Biosimilars Product
Table 89. Kashiv BioSciences Recent Developments/Updates
Table 90. Sandoz Company Information
Table 91. Sandoz Description and Business Overview
Table 92. Sandoz Filgrastim and Biosimilars Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 93. Sandoz Filgrastim and Biosimilars Product
Table 94. Sandoz Recent Developments/Updates
Table 95. Teva Company Information
Table 96. Teva Description and Business Overview
Table 97. Teva Filgrastim and Biosimilars Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 98. Teva Filgrastim and Biosimilars Product
Table 99. Teva Recent Developments/Updates
Table 100. Qilu Pharmaceutical Company Information
Table 101. Qilu Pharmaceutical Description and Business Overview
Table 102. Qilu Pharmaceutical Filgrastim and Biosimilars Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 103. Qilu Pharmaceutical Filgrastim and Biosimilars Product
Table 104. Qilu Pharmaceutical Recent Developments/Updates
Table 105. Harbin Pharmaceutical Group Company Information
Table 106. Harbin Pharmaceutical Group Description and Business Overview
Table 107. Harbin Pharmaceutical Group Filgrastim and Biosimilars Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 108. Harbin Pharmaceutical Group Filgrastim and Biosimilars Product
Table 109. Harbin Pharmaceutical Group Recent Developments/Updates
Table 110. Chengdu Institute of Biological Products Company Information
Table 111. Chengdu Institute of Biological Products Description and Business Overview
Table 112. Chengdu Institute of Biological Products Filgrastim and Biosimilars Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 113. Chengdu Institute of Biological Products Filgrastim and Biosimilars Product
Table 114. Chengdu Institute of Biological Products Recent Developments/Updates
Table 115. CSPC Baike Biopharma Company Information
Table 116. CSPC Baike Biopharma Description and Business Overview
Table 117. CSPC Baike Biopharma Filgrastim and Biosimilars Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 118. CSPC Baike Biopharma Filgrastim and Biosimilars Product
Table 119. CSPC Baike Biopharma Recent Developments/Updates
Table 120. Shanghai Sunway Biotech Company Information
Table 121. Shanghai Sunway Biotech Description and Business Overview
Table 122. Shanghai Sunway Biotech Filgrastim and Biosimilars Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 123. Shanghai Sunway Biotech Filgrastim and Biosimilars Product
Table 124. Shanghai Sunway Biotech Recent Developments/Updates
Table 125. Changchun GeneScience Pharmaceutical Company Information
Table 126. Changchun GeneScience Pharmaceutical Description and Business Overview
Table 127. Changchun GeneScience Pharmaceutical Filgrastim and Biosimilars Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 128. Changchun GeneScience Pharmaceutical Filgrastim and Biosimilars Product
Table 129. Changchun GeneScience Pharmaceutical Recent Developments/Updates
Table 130. Amoytop Biotech Company Information
Table 131. Amoytop Biotech Description and Business Overview
Table 132. Amoytop Biotech Filgrastim and Biosimilars Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 133. Amoytop Biotech Filgrastim and Biosimilars Product
Table 134. Amoytop Biotech Recent Developments/Updates
Table 135. North China Pharmaceutical Company Information
Table 136. North China Pharmaceutical Description and Business Overview
Table 137. North China Pharmaceutical Filgrastim and Biosimilars Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 138. North China Pharmaceutical Filgrastim and Biosimilars Product
Table 139. North China Pharmaceutical Recent Developments/Updates
Table 140. Kexing Biopharm Company Information
Table 141. Kexing Biopharm Description and Business Overview
Table 142. Kexing Biopharm Filgrastim and Biosimilars Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 143. Kexing Biopharm Filgrastim and Biosimilars Product
Table 144. Kexing Biopharm Recent Developments/Updates
Table 145. SL Pharm Company Information
Table 146. SL Pharm Description and Business Overview
Table 147. SL Pharm Filgrastim and Biosimilars Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 148. SL Pharm Filgrastim and Biosimilars Product
Table 149. SL Pharm Recent Developments/Updates
Table 150. Hangzhou Jiuyuan Gene Engineering Company Information
Table 151. Hangzhou Jiuyuan Gene Engineering Description and Business Overview
Table 152. Hangzhou Jiuyuan Gene Engineering Filgrastim and Biosimilars Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 153. Hangzhou Jiuyuan Gene Engineering Filgrastim and Biosimilars Product
Table 154. Hangzhou Jiuyuan Gene Engineering Recent Developments/Updates
Table 155. Jiangsu Wuzhong Pharmaceutical Company Information
Table 156. Jiangsu Wuzhong Pharmaceutical Description and Business Overview
Table 157. Jiangsu Wuzhong Pharmaceutical Filgrastim and Biosimilars Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 158. Jiangsu Wuzhong Pharmaceutical Filgrastim and Biosimilars Product
Table 159. Jiangsu Wuzhong Pharmaceutical Recent Developments/Updates
Table 160. Key Raw Materials Lists
Table 161. Raw Materials Key Suppliers Lists
Table 162. Filgrastim and Biosimilars Distributors List
Table 163. Filgrastim and Biosimilars Customers List
Table 164. Filgrastim and Biosimilars Market Trends
Table 165. Filgrastim and Biosimilars Market Drivers
Table 166. Filgrastim and Biosimilars Market Challenges
Table 167. Filgrastim and Biosimilars Market Restraints
Table 168. Research Programs/Design for This Report
Table 169. Key Data Information from Secondary Sources
Table 170. Key Data Information from Primary Sources
Table 171. Authors List of This Report
List of Figures
Figure 1. Product Picture of Filgrastim and Biosimilars
Figure 2. Global Filgrastim and Biosimilars Market Value by Type (US$ Million), 2021–2032
Figure 3. Global Filgrastim and Biosimilars Market Share by Type: 2025 & 2032
Figure 4. Single-use Vials Product Picture
Figure 5. Prefilled Syringes Product Picture
Figure 6. Global Filgrastim and Biosimilars Market Value by Application (US$ Million), 2021–2032
Figure 7. Global Filgrastim and Biosimilars Market Share by Application: 2025 & 2032
Figure 8. Hospital and Clinic
Figure 9. Pharmacy
Figure 10. Other
Figure 11. Global Filgrastim and Biosimilars Revenue, (US$ Million), 2021 vs 2025 vs 2032
Figure 12. Global Filgrastim and Biosimilars Market Size (US$ Million), 2021–2032
Figure 13. Global Filgrastim and Biosimilars Sales (K Units), 2021–2032
Figure 14. Global Filgrastim and Biosimilars Average Price (US$/Unit), 2021–2032
Figure 15. Filgrastim and Biosimilars Report Years Considered
Figure 16. Filgrastim and Biosimilars Sales Share by Manufacturers in 2025
Figure 17. Global Filgrastim and Biosimilars Revenue Share by Manufacturers in 2025
Figure 18. Top 5 and Top 10 Global Filgrastim and Biosimilars Players: Market Share by Revenue in Filgrastim and Biosimilars in 2025
Figure 19. Filgrastim and Biosimilars Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2021 vs 2025
Figure 20. Global Filgrastim and Biosimilars Market Size by Region (US$ Million): 2021 vs 2025 vs 2032
Figure 21. North America Filgrastim and Biosimilars Sales Market Share by Country (2021–2032)
Figure 22. North America Filgrastim and Biosimilars Revenue Market Share by Country (2021–2032)
Figure 23. United States Filgrastim and Biosimilars Revenue Growth Rate (US$ Million), 2021–2032
Figure 24. Canada Filgrastim and Biosimilars Revenue Growth Rate (US$ Million), 2021–2032
Figure 25. Europe Filgrastim and Biosimilars Sales Market Share by Country (2021–2032)
Figure 26. Europe Filgrastim and Biosimilars Revenue Market Share by Country (2021–2032)
Figure 27. Germany Filgrastim and Biosimilars Revenue Growth Rate (US$ Million), 2021–2032
Figure 28. France Filgrastim and Biosimilars Revenue Growth Rate (US$ Million), 2021–2032
Figure 29. U.K. Filgrastim and Biosimilars Revenue Growth Rate (US$ Million), 2021–2032
Figure 30. Italy Filgrastim and Biosimilars Revenue Growth Rate (US$ Million), 2021–2032
Figure 31. Russia Filgrastim and Biosimilars Revenue Growth Rate (US$ Million), 2021–2032
Figure 32. Asia Pacific Filgrastim and Biosimilars Sales Market Share by Region (2021–2032)
Figure 33. Asia Pacific Filgrastim and Biosimilars Revenue Market Share by Region (2021–2032)
Figure 34. China Filgrastim and Biosimilars Revenue Growth Rate (US$ Million), 2021–2032
Figure 35. Japan Filgrastim and Biosimilars Revenue Growth Rate (US$ Million), 2021–2032
Figure 36. South Korea Filgrastim and Biosimilars Revenue Growth Rate (US$ Million), 2021–2032
Figure 37. India Filgrastim and Biosimilars Revenue Growth Rate (US$ Million), 2021–2032
Figure 38. Australia Filgrastim and Biosimilars Revenue Growth Rate (US$ Million), 2021–2032
Figure 39. China Taiwan Filgrastim and Biosimilars Revenue Growth Rate (US$ Million), 2021–2032
Figure 40. Southeast Asia Filgrastim and Biosimilars Revenue Growth Rate (US$ Million), 2021–2032
Figure 41. Latin America Filgrastim and Biosimilars Sales Market Share by Country (2021–2032)
Figure 42. Latin America Filgrastim and Biosimilars Revenue Market Share by Country (2021–2032)
Figure 43. Mexico Filgrastim and Biosimilars Revenue Growth Rate (US$ Million), 2021–2032
Figure 44. Brazil Filgrastim and Biosimilars Revenue Growth Rate (US$ Million), 2021–2032
Figure 45. Argentina Filgrastim and Biosimilars Revenue Growth Rate (US$ Million), 2021–2032
Figure 46. Colombia Filgrastim and Biosimilars Revenue Growth Rate (US$ Million), 2021–2032
Figure 47. Middle East and Africa Filgrastim and Biosimilars Sales Market Share by Country (2021–2032)
Figure 48. Middle East and Africa Filgrastim and Biosimilars Revenue Market Share by Country (2021–2032)
Figure 49. Turkey Filgrastim and Biosimilars Revenue Growth Rate (US$ Million), 2021–2032
Figure 50. Saudi Arabia Filgrastim and Biosimilars Revenue Growth Rate (US$ Million), 2021–2032
Figure 51. UAE Filgrastim and Biosimilars Revenue Growth Rate (US$ Million), 2021–2032
Figure 52. Global Sales Market Share of Filgrastim and Biosimilars by Type (2021–2032)
Figure 53. Global Revenue Market Share of Filgrastim and Biosimilars by Type (2021–2032)
Figure 54. Global Filgrastim and Biosimilars Price (US$/Unit) by Type (2021–2032)
Figure 55. Global Sales Market Share of Filgrastim and Biosimilars by Application (2021–2032)
Figure 56. Global Revenue Market Share of Filgrastim and Biosimilars by Application (2021–2032)
Figure 57. Global Filgrastim and Biosimilars Price (US$/Unit) by Application (2021–2032)
Figure 58. Filgrastim and Biosimilars Value Chain
Figure 59. Channels of Distribution (Direct Vs Distribution)
Figure 60. Bottom-up and Top-down Approaches for This Report
Figure 61. Data Triangulation
Figure 62. Key Executives Interviewed
Table 1. Global Filgrastim and Biosimilars Market Value by Type (US$ Million), 2025 vs 2032
Table 2. Global Filgrastim and Biosimilars Market Value by Application (US$ Million), 2025 vs 2032
Table 3. Global Filgrastim and Biosimilars Market Competitive Situation by Manufacturers in 2025
Table 4. Global Filgrastim and Biosimilars Sales (K Units) of Key Manufacturers (2021–2026)
Table 5. Global Filgrastim and Biosimilars Sales Market Share by Manufacturers (2021–2026)
Table 6. Global Filgrastim and Biosimilars Revenue (US$ Million) by Manufacturers (2021–2026)
Table 7. Global Filgrastim and Biosimilars Revenue Share by Manufacturers (2021–2026)
Table 8. Global Market Filgrastim and Biosimilars Average Price (US$/Unit) of Key Manufacturers (2021–2026)
Table 9. Global Key Players of Filgrastim and Biosimilars, Industry Ranking, 2023 vs 2024 vs 2025
Table 10. Global Key Manufacturers of Filgrastim and Biosimilars, Manufacturing Sites and Headquarters
Table 11. Global Key Manufacturers of Filgrastim and Biosimilars, Product Types and Applications
Table 12. Global Key Manufacturers of Filgrastim and Biosimilars, Date of Entry into the Industry
Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Global Filgrastim and Biosimilars Companies by Tier (Tier 1, Tier 2, Tier 3), based on Filgrastim and Biosimilars Revenue, 2025
Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 16. Global Filgrastim and Biosimilars Market Size by Region (US$ Million): 2021 vs 2025 vs 2032
Table 17. Global Filgrastim and Biosimilars Sales by Region (K Units), 2021–2026
Table 18. Global Filgrastim and Biosimilars Sales Market Share by Region (2021–2026)
Table 19. Global Filgrastim and Biosimilars Sales by Region (K Units), 2027–2032
Table 20. Global Filgrastim and Biosimilars Sales Market Share by Region (2027–2032)
Table 21. Global Filgrastim and Biosimilars Revenue by Region (US$ Million), 2021–2026
Table 22. Global Filgrastim and Biosimilars Revenue Market Share by Region (2021–2026)
Table 23. Global Filgrastim and Biosimilars Revenue by Region (US$ Million), 2027–2032
Table 24. Global Filgrastim and Biosimilars Revenue Market Share by Region (2027–2032)
Table 25. North America Filgrastim and Biosimilars Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 26. North America Filgrastim and Biosimilars Sales by Country (K Units), 2021–2026
Table 27. North America Filgrastim and Biosimilars Sales by Country (K Units), 2027–2032
Table 28. North America Filgrastim and Biosimilars Revenue by Country (US$ Million), 2021–2026
Table 29. North America Filgrastim and Biosimilars Revenue by Country (US$ Million), 2027–2032
Table 30. Europe Filgrastim and Biosimilars Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 31. Europe Filgrastim and Biosimilars Sales by Country (K Units), 2021–2026
Table 32. Europe Filgrastim and Biosimilars Sales by Country (K Units), 2027–2032
Table 33. Europe Filgrastim and Biosimilars Revenue by Country (US$ Million), 2021–2026
Table 34. Europe Filgrastim and Biosimilars Revenue by Country (US$ Million), 2027–2032
Table 35. Asia Pacific Filgrastim and Biosimilars Revenue by Region: 2021 vs 2025 vs 2032 (US$ Million)
Table 36. Asia Pacific Filgrastim and Biosimilars Sales by Region (K Units), 2021–2026
Table 37. Asia Pacific Filgrastim and Biosimilars Sales by Region (K Units), 2027–2032
Table 38. Asia Pacific Filgrastim and Biosimilars Revenue by Region (US$ Million), 2021–2026
Table 39. Asia Pacific Filgrastim and Biosimilars Revenue by Region (US$ Million), 2027–2032
Table 40. Latin America Filgrastim and Biosimilars Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 41. Latin America Filgrastim and Biosimilars Sales by Country (K Units), 2021–2026
Table 42. Latin America Filgrastim and Biosimilars Sales by Country (K Units), 2027–2032
Table 43. Latin America Filgrastim and Biosimilars Revenue by Country (US$ Million), 2021–2026
Table 44. Latin America Filgrastim and Biosimilars Revenue by Country (US$ Million), 2027–2032
Table 45. Middle East and Africa Filgrastim and Biosimilars Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 46. Middle East and Africa Filgrastim and Biosimilars Sales by Country (K Units), 2021–2026
Table 47. Middle East and Africa Filgrastim and Biosimilars Sales by Country (K Units), 2027–2032
Table 48. Middle East and Africa Filgrastim and Biosimilars Revenue by Country (US$ Million), 2021–2026
Table 49. Middle East and Africa Filgrastim and Biosimilars Revenue by Country (US$ Million), 2027–2032
Table 50. Global Filgrastim and Biosimilars Sales (K Units) by Type (2021–2026)
Table 51. Global Filgrastim and Biosimilars Sales (K Units) by Type (2027–2032)
Table 52. Global Filgrastim and Biosimilars Sales Market Share by Type (2021–2026)
Table 53. Global Filgrastim and Biosimilars Sales Market Share by Type (2027–2032)
Table 54. Global Filgrastim and Biosimilars Revenue (US$ Million) by Type (2021–2026)
Table 55. Global Filgrastim and Biosimilars Revenue (US$ Million) by Type (2027–2032)
Table 56. Global Filgrastim and Biosimilars Revenue Market Share by Type (2021–2026)
Table 57. Global Filgrastim and Biosimilars Revenue Market Share by Type (2027–2032)
Table 58. Global Filgrastim and Biosimilars Price (US$/Unit) by Type (2021–2026)
Table 59. Global Filgrastim and Biosimilars Price (US$/Unit) by Type (2027–2032)
Table 60. Global Filgrastim and Biosimilars Sales (K Units) by Application (2021–2026)
Table 61. Global Filgrastim and Biosimilars Sales (K Units) by Application (2027–2032)
Table 62. Global Filgrastim and Biosimilars Sales Market Share by Application (2021–2026)
Table 63. Global Filgrastim and Biosimilars Sales Market Share by Application (2027–2032)
Table 64. Global Filgrastim and Biosimilars Revenue (US$ Million) by Application (2021–2026)
Table 65. Global Filgrastim and Biosimilars Revenue (US$ Million) by Application (2027–2032)
Table 66. Global Filgrastim and Biosimilars Revenue Market Share by Application (2021–2026)
Table 67. Global Filgrastim and Biosimilars Revenue Market Share by Application (2027–2032)
Table 68. Global Filgrastim and Biosimilars Price (US$/Unit) by Application (2021–2026)
Table 69. Global Filgrastim and Biosimilars Price (US$/Unit) by Application (2027–2032)
Table 70. Amgen Company Information
Table 71. Amgen Description and Business Overview
Table 72. Amgen Filgrastim and Biosimilars Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 73. Amgen Filgrastim and Biosimilars Product
Table 74. Amgen Recent Developments/Updates
Table 75. Pfizer Company Information
Table 76. Pfizer Description and Business Overview
Table 77. Pfizer Filgrastim and Biosimilars Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 78. Pfizer Filgrastim and Biosimilars Product
Table 79. Pfizer Recent Developments/Updates
Table 80. Tanvex BioPharma Company Information
Table 81. Tanvex BioPharma Description and Business Overview
Table 82. Tanvex BioPharma Filgrastim and Biosimilars Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 83. Tanvex BioPharma Filgrastim and Biosimilars Product
Table 84. Tanvex BioPharma Recent Developments/Updates
Table 85. Kashiv BioSciences Company Information
Table 86. Kashiv BioSciences Description and Business Overview
Table 87. Kashiv BioSciences Filgrastim and Biosimilars Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 88. Kashiv BioSciences Filgrastim and Biosimilars Product
Table 89. Kashiv BioSciences Recent Developments/Updates
Table 90. Sandoz Company Information
Table 91. Sandoz Description and Business Overview
Table 92. Sandoz Filgrastim and Biosimilars Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 93. Sandoz Filgrastim and Biosimilars Product
Table 94. Sandoz Recent Developments/Updates
Table 95. Teva Company Information
Table 96. Teva Description and Business Overview
Table 97. Teva Filgrastim and Biosimilars Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 98. Teva Filgrastim and Biosimilars Product
Table 99. Teva Recent Developments/Updates
Table 100. Qilu Pharmaceutical Company Information
Table 101. Qilu Pharmaceutical Description and Business Overview
Table 102. Qilu Pharmaceutical Filgrastim and Biosimilars Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 103. Qilu Pharmaceutical Filgrastim and Biosimilars Product
Table 104. Qilu Pharmaceutical Recent Developments/Updates
Table 105. Harbin Pharmaceutical Group Company Information
Table 106. Harbin Pharmaceutical Group Description and Business Overview
Table 107. Harbin Pharmaceutical Group Filgrastim and Biosimilars Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 108. Harbin Pharmaceutical Group Filgrastim and Biosimilars Product
Table 109. Harbin Pharmaceutical Group Recent Developments/Updates
Table 110. Chengdu Institute of Biological Products Company Information
Table 111. Chengdu Institute of Biological Products Description and Business Overview
Table 112. Chengdu Institute of Biological Products Filgrastim and Biosimilars Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 113. Chengdu Institute of Biological Products Filgrastim and Biosimilars Product
Table 114. Chengdu Institute of Biological Products Recent Developments/Updates
Table 115. CSPC Baike Biopharma Company Information
Table 116. CSPC Baike Biopharma Description and Business Overview
Table 117. CSPC Baike Biopharma Filgrastim and Biosimilars Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 118. CSPC Baike Biopharma Filgrastim and Biosimilars Product
Table 119. CSPC Baike Biopharma Recent Developments/Updates
Table 120. Shanghai Sunway Biotech Company Information
Table 121. Shanghai Sunway Biotech Description and Business Overview
Table 122. Shanghai Sunway Biotech Filgrastim and Biosimilars Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 123. Shanghai Sunway Biotech Filgrastim and Biosimilars Product
Table 124. Shanghai Sunway Biotech Recent Developments/Updates
Table 125. Changchun GeneScience Pharmaceutical Company Information
Table 126. Changchun GeneScience Pharmaceutical Description and Business Overview
Table 127. Changchun GeneScience Pharmaceutical Filgrastim and Biosimilars Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 128. Changchun GeneScience Pharmaceutical Filgrastim and Biosimilars Product
Table 129. Changchun GeneScience Pharmaceutical Recent Developments/Updates
Table 130. Amoytop Biotech Company Information
Table 131. Amoytop Biotech Description and Business Overview
Table 132. Amoytop Biotech Filgrastim and Biosimilars Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 133. Amoytop Biotech Filgrastim and Biosimilars Product
Table 134. Amoytop Biotech Recent Developments/Updates
Table 135. North China Pharmaceutical Company Information
Table 136. North China Pharmaceutical Description and Business Overview
Table 137. North China Pharmaceutical Filgrastim and Biosimilars Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 138. North China Pharmaceutical Filgrastim and Biosimilars Product
Table 139. North China Pharmaceutical Recent Developments/Updates
Table 140. Kexing Biopharm Company Information
Table 141. Kexing Biopharm Description and Business Overview
Table 142. Kexing Biopharm Filgrastim and Biosimilars Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 143. Kexing Biopharm Filgrastim and Biosimilars Product
Table 144. Kexing Biopharm Recent Developments/Updates
Table 145. SL Pharm Company Information
Table 146. SL Pharm Description and Business Overview
Table 147. SL Pharm Filgrastim and Biosimilars Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 148. SL Pharm Filgrastim and Biosimilars Product
Table 149. SL Pharm Recent Developments/Updates
Table 150. Hangzhou Jiuyuan Gene Engineering Company Information
Table 151. Hangzhou Jiuyuan Gene Engineering Description and Business Overview
Table 152. Hangzhou Jiuyuan Gene Engineering Filgrastim and Biosimilars Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 153. Hangzhou Jiuyuan Gene Engineering Filgrastim and Biosimilars Product
Table 154. Hangzhou Jiuyuan Gene Engineering Recent Developments/Updates
Table 155. Jiangsu Wuzhong Pharmaceutical Company Information
Table 156. Jiangsu Wuzhong Pharmaceutical Description and Business Overview
Table 157. Jiangsu Wuzhong Pharmaceutical Filgrastim and Biosimilars Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 158. Jiangsu Wuzhong Pharmaceutical Filgrastim and Biosimilars Product
Table 159. Jiangsu Wuzhong Pharmaceutical Recent Developments/Updates
Table 160. Key Raw Materials Lists
Table 161. Raw Materials Key Suppliers Lists
Table 162. Filgrastim and Biosimilars Distributors List
Table 163. Filgrastim and Biosimilars Customers List
Table 164. Filgrastim and Biosimilars Market Trends
Table 165. Filgrastim and Biosimilars Market Drivers
Table 166. Filgrastim and Biosimilars Market Challenges
Table 167. Filgrastim and Biosimilars Market Restraints
Table 168. Research Programs/Design for This Report
Table 169. Key Data Information from Secondary Sources
Table 170. Key Data Information from Primary Sources
Table 171. Authors List of This Report
List of Figures
Figure 1. Product Picture of Filgrastim and Biosimilars
Figure 2. Global Filgrastim and Biosimilars Market Value by Type (US$ Million), 2021–2032
Figure 3. Global Filgrastim and Biosimilars Market Share by Type: 2025 & 2032
Figure 4. Single-use Vials Product Picture
Figure 5. Prefilled Syringes Product Picture
Figure 6. Global Filgrastim and Biosimilars Market Value by Application (US$ Million), 2021–2032
Figure 7. Global Filgrastim and Biosimilars Market Share by Application: 2025 & 2032
Figure 8. Hospital and Clinic
Figure 9. Pharmacy
Figure 10. Other
Figure 11. Global Filgrastim and Biosimilars Revenue, (US$ Million), 2021 vs 2025 vs 2032
Figure 12. Global Filgrastim and Biosimilars Market Size (US$ Million), 2021–2032
Figure 13. Global Filgrastim and Biosimilars Sales (K Units), 2021–2032
Figure 14. Global Filgrastim and Biosimilars Average Price (US$/Unit), 2021–2032
Figure 15. Filgrastim and Biosimilars Report Years Considered
Figure 16. Filgrastim and Biosimilars Sales Share by Manufacturers in 2025
Figure 17. Global Filgrastim and Biosimilars Revenue Share by Manufacturers in 2025
Figure 18. Top 5 and Top 10 Global Filgrastim and Biosimilars Players: Market Share by Revenue in Filgrastim and Biosimilars in 2025
Figure 19. Filgrastim and Biosimilars Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2021 vs 2025
Figure 20. Global Filgrastim and Biosimilars Market Size by Region (US$ Million): 2021 vs 2025 vs 2032
Figure 21. North America Filgrastim and Biosimilars Sales Market Share by Country (2021–2032)
Figure 22. North America Filgrastim and Biosimilars Revenue Market Share by Country (2021–2032)
Figure 23. United States Filgrastim and Biosimilars Revenue Growth Rate (US$ Million), 2021–2032
Figure 24. Canada Filgrastim and Biosimilars Revenue Growth Rate (US$ Million), 2021–2032
Figure 25. Europe Filgrastim and Biosimilars Sales Market Share by Country (2021–2032)
Figure 26. Europe Filgrastim and Biosimilars Revenue Market Share by Country (2021–2032)
Figure 27. Germany Filgrastim and Biosimilars Revenue Growth Rate (US$ Million), 2021–2032
Figure 28. France Filgrastim and Biosimilars Revenue Growth Rate (US$ Million), 2021–2032
Figure 29. U.K. Filgrastim and Biosimilars Revenue Growth Rate (US$ Million), 2021–2032
Figure 30. Italy Filgrastim and Biosimilars Revenue Growth Rate (US$ Million), 2021–2032
Figure 31. Russia Filgrastim and Biosimilars Revenue Growth Rate (US$ Million), 2021–2032
Figure 32. Asia Pacific Filgrastim and Biosimilars Sales Market Share by Region (2021–2032)
Figure 33. Asia Pacific Filgrastim and Biosimilars Revenue Market Share by Region (2021–2032)
Figure 34. China Filgrastim and Biosimilars Revenue Growth Rate (US$ Million), 2021–2032
Figure 35. Japan Filgrastim and Biosimilars Revenue Growth Rate (US$ Million), 2021–2032
Figure 36. South Korea Filgrastim and Biosimilars Revenue Growth Rate (US$ Million), 2021–2032
Figure 37. India Filgrastim and Biosimilars Revenue Growth Rate (US$ Million), 2021–2032
Figure 38. Australia Filgrastim and Biosimilars Revenue Growth Rate (US$ Million), 2021–2032
Figure 39. China Taiwan Filgrastim and Biosimilars Revenue Growth Rate (US$ Million), 2021–2032
Figure 40. Southeast Asia Filgrastim and Biosimilars Revenue Growth Rate (US$ Million), 2021–2032
Figure 41. Latin America Filgrastim and Biosimilars Sales Market Share by Country (2021–2032)
Figure 42. Latin America Filgrastim and Biosimilars Revenue Market Share by Country (2021–2032)
Figure 43. Mexico Filgrastim and Biosimilars Revenue Growth Rate (US$ Million), 2021–2032
Figure 44. Brazil Filgrastim and Biosimilars Revenue Growth Rate (US$ Million), 2021–2032
Figure 45. Argentina Filgrastim and Biosimilars Revenue Growth Rate (US$ Million), 2021–2032
Figure 46. Colombia Filgrastim and Biosimilars Revenue Growth Rate (US$ Million), 2021–2032
Figure 47. Middle East and Africa Filgrastim and Biosimilars Sales Market Share by Country (2021–2032)
Figure 48. Middle East and Africa Filgrastim and Biosimilars Revenue Market Share by Country (2021–2032)
Figure 49. Turkey Filgrastim and Biosimilars Revenue Growth Rate (US$ Million), 2021–2032
Figure 50. Saudi Arabia Filgrastim and Biosimilars Revenue Growth Rate (US$ Million), 2021–2032
Figure 51. UAE Filgrastim and Biosimilars Revenue Growth Rate (US$ Million), 2021–2032
Figure 52. Global Sales Market Share of Filgrastim and Biosimilars by Type (2021–2032)
Figure 53. Global Revenue Market Share of Filgrastim and Biosimilars by Type (2021–2032)
Figure 54. Global Filgrastim and Biosimilars Price (US$/Unit) by Type (2021–2032)
Figure 55. Global Sales Market Share of Filgrastim and Biosimilars by Application (2021–2032)
Figure 56. Global Revenue Market Share of Filgrastim and Biosimilars by Application (2021–2032)
Figure 57. Global Filgrastim and Biosimilars Price (US$/Unit) by Application (2021–2032)
Figure 58. Filgrastim and Biosimilars Value Chain
Figure 59. Channels of Distribution (Direct Vs Distribution)
Figure 60. Bottom-up and Top-down Approaches for This Report
Figure 61. Data Triangulation
Figure 62. Key Executives Interviewed
Our team would be happy to assist you with your queries.
About us
Accurate data, The latest market trends, And deeper research directions.
Our sole purpose is to provide a basis for leaders in all walks of life to make more appropriate decisions, to help companies solve existing problems and achieve business goals
Latest reports
Global Sales Planning Tool Market Research Report 2026
Feb 03, 26
Global Chromium Oxide Powder Market Research Report 2026
Feb 03, 26
Global Shape Memory Actuator Market Research Report 2026
Feb 03, 26
Useful links
Our Contacts
Room 2306, T6 Fuxing World Financial Center, Kaifu District, Changsha, Hunan, China
(+86) 159 1069 5232